Amniotic Membrane Market: Thriving Utility in Ophthalmology An amniotic membrane (AM), the innermost layer of the placenta, encompasses a combination of cells and tissues that promote epithelialization while minimizing scarring, neovascularization, and inflammation. As per Inkwood Research, the global amniotic membrane market is set to reach a revenue of $2891.80 million by 2032, projecting a CAGR of 7.27% during the forecast period, 20232032.
The amniotic membrane is elastic, lightweight, thin, and almost transparent, making it viable for use on the eye surface. Accordingly, it is used in the surgical management of varied ophthalmic conditions.
Amniotic Membrane’s Thriving Utility in Ophthalmology According to the World Health Organization (WHO), around 2.2 million people globally have near or distant vision impairment. Amniotic membrane transplantation (AMT) is used in varied ways to treat several ophthalmic conditions. The membrane may serve either as a temporary patch, permanent graft, or a combination of both. As a graft, the amniotic membrane is placed at the site of a conjunctival or corneal tissue defect caused by surgery or disease. The graft placed epithelial side up facilitates a basement membrane and stroma wherein normal epithelium can grow. It helps minimize scarring & inflammation and eventually integrates into the host tissue.